Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Anixa Biosciences Inc (ANIX)

Anixa Biosciences Inc (ANIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 146,755
  • Shares Outstanding, K 29,950
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,020 K
  • 60-Month Beta 1.47
  • Price/Sales 258.51
  • Price/Cash Flow N/A
  • Price/Book 4.54
Trade ANIX with:

Options Overview

Details
  • Implied Volatility 103.63%
  • Historical Volatility 62.12%
  • IV Percentile 27%
  • IV Rank 36.42%
  • IV High 167.35% on 07/07/21
  • IV Low 67.13% on 06/24/21
  • Put/Call Vol Ratio 0.03
  • Today's Volume 122
  • Volume Avg (30-Day) 468
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,455
  • Open Int (30-Day) 1,728

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 10/31/21
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.81
  • Growth Rate Est. (year over year) +88.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.03 +21.72%
on 08/18/21
5.87 -16.52%
on 08/30/21
+0.86 (+21.29%)
since 08/17/21
3-Month
3.48 +40.80%
on 07/07/21
5.87 -16.52%
on 08/30/21
+0.77 (+18.64%)
since 06/17/21
52-Week
1.91 +156.54%
on 11/09/20
8.09 -39.43%
on 03/18/21
+2.54 (+107.19%)
since 09/17/20

Most Recent Stories

More News
Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming Emerging Immunotherapeutics for Ovarian Cancer Symposium

/PRNewswire/ --  (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the inventor of its ovarian cancer CAR-T technology,...

ANIX : 4.90 (+1.66%)
Anixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer

/PRNewswire/ -- (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today the appointment of , Ph.D., as Chief Development Officer. ...

ANIX : 4.90 (+1.66%)
Anixa (ANIX) Ovarian Cancer CAR-T Drug to Enter Clinical Study

The FDA clears Anixa Biosciences' (ANIX) application to initiate clinical studies for its ovarian cancer CAR-T therapy. The stock rises following the announcement.

REGN : 651.88 (-0.20%)
IRWD : 12.35 (+2.24%)
HZNP : 109.71 (+1.63%)
ANIX : 4.90 (+1.66%)
Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate Clinical Trial of Ovarian Cancer CAR-T Immunotherapy

/PRNewswire/ --  (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has...

ANIX : 4.90 (+1.66%)
Anixa Biosciences' Covid-19 Compounds Expected to be Effective Against the Delta Variant

/PRNewswire/ --  (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that a genomic variant analysis indicates that its potential...

ANIX : 4.90 (+1.66%)
Anixa Biosciences Congratulates Director, Dr. Arnold Baskies for His Appointment to the WHO's Global Breast Cancer Initiative

/PRNewswire/ --  (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Director, Dr. has been appointed to the World...

ANIX : 4.90 (+1.66%)
Anixa Biosciences Announces Issuance of U.S. Patent for Ovarian Cancer Vaccine Technology

/PRNewswire/ --  (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Patent and Trademark Office has issued...

ANIX : 4.90 (+1.66%)
Anixa Biosciences Announces Support from the National Cancer Institute for Ovarian Cancer Vaccine Developed by Cleveland Clinic

, /PRNewswire/ --  (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that its ovarian cancer vaccine technology is part...

ANIX : 4.90 (+1.66%)
Anixa Biosciences and Moffitt Cancer Center Receive Additional Information Request from US FDA for CAR-T IND Application

, /PRNewswire/ --  (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (US FDA)...

ANIX : 4.90 (+1.66%)
OntoChem Assigns Anixa Covid-19 Drug Discovery Project to MolGenie

, , /PRNewswire/ -- OntoChem GmbH, a German Life Science IT company, announced today that it has assigned its drug discovery technologies and assets, including its drug discovery collaboration with Anixa...

ANIX : 4.90 (+1.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States.

See More

Key Turning Points

3rd Resistance Point 5.43
2nd Resistance Point 5.19
1st Resistance Point 5.04
Last Price 4.90
1st Support Level 4.65
2nd Support Level 4.41
3rd Support Level 4.26

See More

52-Week High 8.09
Fibonacci 61.8% 5.73
Fibonacci 50% 5.00
Last Price 4.90
Fibonacci 38.2% 4.27
52-Week Low 1.91

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar